Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure of a MenB de-N-acetyl polysialic acid antibody and mechanism of immune cell inhibition.

The Journal of biological chemistry·2026
Same author

C4BP occludes the non-opsonic interaction of <i>Neisseria gonorrhoeae</i> with human neutrophil CEACAMs.

Infection and immunity·2026
Same author

Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB.

NPJ vaccines·2026
Same author

An adenoviral-vectored vaccine protects mice against aerosol challenge with Yersinia pestis.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

C4BP occludes the non-opsonic interaction of <i>Neisseria gonorrhoeae</i> with human neutrophil CEACAMs.

bioRxiv : the preprint server for biology·2026
Same author

Disseminated gonococcal infection secondary to a rare homozygous mutation resulting in complement factor I deficiency.

Journal of human immunity·2026
Same journal

Correction for Nishimori et al., “Identification of an Atypical Enzootic Bovine Leukosis in Japan by Using a Novel Classification of Bovine Leukemia Based on Immunophenotypic Analysis”

Clinical and vaccine immunology : CVI·2018
Same journal

Effect of Breastfeeding and Additional Household Children on Cytomegalovirus Seroprevalence among U.S. Children 1 to 5 Years of Age.

Clinical and vaccine immunology : CVI·2017
Same journal

Reevaluation of Positivity Cutoff Values for the Pneumococcal Urinary Antigen Detection Assay.

Clinical and vaccine immunology : CVI·2017
Same journal

The Legacy of CVI.

Clinical and vaccine immunology : CVI·2017
Same journal

Protein Structure Facilitates High-Resolution Immunological Mapping.

Clinical and vaccine immunology : CVI·2017
Same journal

Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.

Clinical and vaccine immunology : CVI·2017
See all related articles

Related Experiment Video

Updated: May 10, 2026

Assays for Studying the Role of Vitronectin in Bacterial Adhesion and Serum Resistance
10:55

Assays for Studying the Role of Vitronectin in Bacterial Adhesion and Serum Resistance

Published on: October 16, 2018

Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease

Dan M Granoff1, Sanjay Ram, Peter T Beernink

  • 1Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, CA, USA. dgranoff@chori.org

Clinical and Vaccine Immunology : CVI
|June 7, 2013
PubMed
Summary
This summary is machine-generated.

Factor H binding protein (fHbp) vaccines are used against meningococcal disease. Mutant fHbp vaccines with reduced factor H binding show improved immunogenicity, suggesting better protection against bacterial infections.

More Related Videos

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Related Experiment Videos

Last Updated: May 10, 2026

Assays for Studying the Role of Vitronectin in Bacterial Adhesion and Serum Resistance
10:55

Assays for Studying the Role of Vitronectin in Bacterial Adhesion and Serum Resistance

Published on: October 16, 2018

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Area of Science:

  • Vaccinology
  • Microbiology
  • Immunology

Background:

  • Factor H binding protein (fHbp) is a key antigen in vaccines for preventing serogroup B meningococcal disease.
  • fHbp facilitates bacterial survival by recruiting host factor H (fH) to the bacterial surface, inhibiting complement-mediated lysis.

Purpose of the Study:

  • To review the immunogenicity of fHbp vaccines in human factor H (fH) transgenic mice.
  • To evaluate the impact of fH binding on vaccine efficacy and explore strategies for improving fHbp vaccine immunogenicity.

Main Methods:

  • Review of studies involving fHbp vaccines in human fH transgenic mouse models.
  • Analysis of antibody responses and their correlation with fH concentrations and fHbp mutations.

Main Results:

  • Transgenic mice with high human fH levels exhibited impaired protective antibody responses to fHbp vaccines.
  • Mutant fHbp vaccines with reduced fH binding demonstrated superior immunogenicity, potentially by exposing protective epitopes.
  • Human infant vaccination required additional antigens, increasing local reactions and fever.

Conclusions:

  • Decreased fH binding in mutant fHbp vaccines may enhance immunogenicity in humans, leading to improved protection against meningococcal disease.
  • These findings have implications for developing more effective fHbp vaccines and vaccines against other pathogens that bind host molecules.